| [1] |
Tang ZY. Modern Oncology[M].Third edition.Shanghai:Fudan University Press, 2011: 964-83.[汤钊猷.现代肿瘤学[M]. 3版.上 海:复旦大学出版社, 2011: 964-83.]
|
| [2] |
Xu YJ, Liu YY, Yao ZH, et al. Expression of ercc1 of rrm1 genes in invasive non-hodgkin’s lymphoma and clinical significance[J]. Zhong Liu Fang Zhi Yan Jiu, 2013, 40(5):451-4.[许英君, 刘艳艳, 姚志华, 等. ercc1、rrm1基因在侵袭性非霍奇金淋巴瘤中的表 达及临床意义[J].肿瘤防治研究, 2013, 40(5):451-4.]
|
| [3] |
Gallagher DJ, Konner JA, Bell-McGuinn KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity[J]. Ann Oncol, 20 11, 22(5): 1127-32.
|
| [4] |
Shen DW, Pouliot LM, Hall MD, et al. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes[J]. Pharmacol Rev, 2012, 64(3): 706-21.
|
| [5] |
Croteau DL, Peng Y, Van Houten B. DNA repair gets physical: mapping an XPA-binding site on ERCC1[J]. DNA Repair(Amst),2008, 7(5): 819-26.
|
| [6] |
Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents[J]. Cancer Treat Rev, 20 07, 33(1): 9-23.
|
| [7] |
Xian-Jun F, Xiu-Guang Q, Li Z, et al. ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy[J]. Pak J Med Sci, 20 14, 30(3): 488-92.
|
| [8] |
Li P, Fang YJ, Li F, et al. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy[J]. Br J Cancer, 2013, 108(6): 1238-44.
|
| [9] |
Rosell R, Cobo M, Isla D, et al. Pharmacogenomics and gemcitabine[J]. Ann Oncol, 2006, 17 Suppl 5: v13-16.
|
| [10] |
Weberpals J, Garbuio K, O’Brien A, et al. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer[J]. Int J Cancer, 2009, 124(4): 806-15.
|
| [11] |
Yang Y, Xie Y, Xian L,et al. Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis[J]. J Exp Clin Cancer Res, 2013, 32 : 15.
|
| [12] |
Zeng LH, Wang YX, Xie K, et al. Clinical significance of mRNA expression level of ERCC1，BRCA1 and TYMS gene and polymorphism investigation of UGT1A1 gene in individualized chemotherapy of the patients with advanced colorectal cancer[J]. Xian Dai Yi Yao Wei Sheng, 2014, 30(12): 1761-4.[曾令海, 王亚 旭, 谢凯, 等. ERCC1、BRCA1、TYMS的mRNA 表达水平和 UGT1A1多态性检测在结直肠癌患者个体化化疗中的临床意 义[J] 现代医药卫生, 2014, 30(12): 1761-4.]
|
| [13] |
Xu GH, Li Y, Ye SL, et al. ERCC1 and BRCA1 expressions in the tissues of colorectal cancer and its relationship with clinical significance of platinum-based chemotherapy[J]. Fu Dan Xue Bao(Yi Xue Ban), 2011, 38(4): 315-8,323. [徐光辉, 李玉, 叶胜龙, 等. 结直肠癌组织中ERCC1和BRCA1的表达及其与铂类化疗 疗效的相关性[J]. 复旦学报（医学版）, 2011, 38(4):315-8,323.]
|
下载:
